Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Alair study: Long-term efficacy of Asthmatx's bronchial thermoplasty system is demonstrated by five-year data from the Asthma Intervention Research (AIR) trial, presented May 19 at the American Thoracic Society annual meeting in New Orleans. Results showed that over five years, the percentage of patients reporting respiratory adverse events remained stable; hospitalizations and ER visits for respiratory symptoms remained stable; pulmonary function remained stable; and there were no incidences of pneumothorax, intubation, mechanical ventilation, cardiac arrhythmias or death as a result of treatment with Alair. The system, which delivers thermal energy to reduce excess airway smooth muscle associated with airway constriction, is the first device-based asthma treatment approved by FDA (1"The Gray Sheet" May 3, 2010)
You may also be interested in...
Asthmatx Debuts Alair For Severe Asthma Following PMA Approval
Asthmatx is initiating a "focused launch" of its Alair bronchial thermoplasty system after receiving PMA approval April 27, according to CEO Glen French
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.